

TRUSTEES' REPORT AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED  
31 MARCH 2025

THE UK MYELOMA  
SOCIETY

MENZIES  
BRIGHTER THINKING

---

# THE UK MYELOMA SOCIETY

---

## CONTENTS

---

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 16

---

# THE UK MYELOMA SOCIETY

---

## REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2025

---

<b>Trustees</b>	Dr N Rabin
	Dr C Bygrave
	Dr R Hall
	Dr J Ashcroft
	Prof G Cook
	Prof G Pratt
	Prof M Kaiser
	Dr K Ramasamy
	Dr R Popat
	Dr M Jenner
	Dr J Sive
	Dr S Lawless
	Dr R Soutar
	Dr S Lawson
	J Quinn
	Dr J Travers
	C Loughran
	Dr S Moore
	Dr T Chan (appointed 13 November 2024)
<b>Charity registered number</b>	1082702
<b>Principal office</b>	Pathology Building, Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield WF1 4DG
<b>Independent examiner</b>	Menzies LLP Chartered Accountants Magna House 18-32 London Road Staines-Upon-Thames TW18 4BP
<b>Bankers</b>	Coutts & Co 440 Strand London WC2R 0QS

---

# THE UK MYELOMA SOCIETY

---

## TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2025

---

The Trustees present their annual report together with the financial statements of the Charity for the 1 April 2024 to 31 March 2025.

### Objectives and activities

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

The UKMS had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2024; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

### Revenue

- Revenue received for corporate sponsorship contributed £112,420 (April 2024 - March 2025). This re-enforces the support by pharma for the work that the UKMS undertakes
- Separately, £33,000 was raised by Hartley Taylor Medical Communications Ltd from pharma (GSK, J&J, Sanofi x £10k + Amgen £3k) to support for the UKMRA Away Day on the 16 - 17 January 2025 in York
- In addition, £5,250 was raised from Pharma for the UKMS Pharmacy Education Day on the 5 November 2024 at the Wellcome Collection (Sanofi £1,500, J&J £1,750, Menarini Stemline £1,500, BMS £250 and Pfizer £250)

### Education

The Autumn Day was held on 14th November 2024, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was 'UK Myeloma Society at 25: Achievements and Future Directions' and featured Professor Gordon Cook from the University of Leeds. He presented the Michael Morley Lecture on Frailty in Myeloma.

The Spring Day was also a hybrid meeting and was held on 19th March 2025. The theme for this meeting was the 'Optimising Outcomes in Myeloma'. The plenary lecture was given by Professor Sigurður Kristinnsson from the University of Iceland. His talk was entitled, 'Results from the Iceland screens, treats or prevents multiple myeloma (iStopMM) study.

### Travel Bursaries

A total of six travel bursaries for scientific conferences were awarded in 2024 to winning abstracts;

- 2 x ASH San Diego £1,200 each
- 2 x EHA Madrid £900 each
- 2 X IMS Rio de Janeiro £1,200 each

The abstracts were presented at the subsequent Autumn / Spring Days in either November 2024 or March 2025. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e-newsletter.

### Achievements and performance

#### Education: The annual meetings

Production of two successful and well attended educational hybrid meetings in November 2024 and March 2025. For full programme details, please refer to the section above and the UKMS website.

---

# THE UK MYELOMA SOCIETY

---

## TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

---

### **Travel Bursaries for scientific meetings**

The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2024-25 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2024-25. Further details can be found above.

### **Advocacy**

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

### **The Guidelines group**

The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients.

Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting.

There have been three important guidelines published in the British Journal of Haematology. These include the good practice papers on imaging and high-risk myeloma and the guideline on the diagnosis and management of monoclonal gammopathy of renal significance. These are also available for viewing on the BSH and UKMS web sites.

The guidelines on relapsed/refractory myeloma and amyloidosis screening; the management of myeloma bone disease and the use of bispecific antibodies in relapsed/refractory myeloma also in the early stages of planning.

Dr Simon Stern has stepped down as the Chair of the UKMS Guidelines Group and Dr Tracey Chan has taken over as Chair from March 2025.

### **UKMRA - UK Myeloma Research Alliance**

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 14th May 2024. On the 16 - 17 January 2025, the UKMRA held the annual Away Day at the Principle Hotel in York. Around 40 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials.

### **Myeloma Nurse Group**

Jackie Quinn has chaired the Nurse group since November 2023.

Projects and discussion for 2024 included;

- Develop protocol for Self-administration of Velcade
- Explored the potential for nurse webinars co-partnered with Myeloma UK
- Worked with Myeloma UK to produce a nurse network to support all haematology CNSs across the UK
- The inaugural Nurse Education Study Day took place on 11 March 2025 at the Wellcome Collection
- The group continue to work with the Pharmacy group adapting an online tool Myeloma treatment scheduler called 'MyeTx Scheduler' which is tool to create an individual MM treatment schedule to aid understanding and compliance

### **Myeloma Pharmacy Group**

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 5 November 2024, the group held the Pharmacy Education Day at the Wellcome Collection in central London.

# THE UK MYELOMA SOCIETY

## TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2024 fellows: Sarah Henshaw  
Professor Jamie Cavenagh  
Dr John Ashcroft

### Financial review

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

### Income

- Education Grants from Corporate Sponsors contributed approximately £112,420 in 2024
- Income from Pharmacy Day Sponsorship 5 November 2024 - £5,250
- A £12,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 24-25
- UKMRA Away Day January 2025, Principle Hotel in York Sponsorship revenue £33,000 (GSK, J&J, Sanofi x £10k + Amgen £3k)

### The Michael Morley Fund

This fund is from a patients estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

### Investments

CCLA Ethical Charity Investments £56,171

### Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance). £40,000. Instructed new Accountants, Menzies annual fee £3,200.

### UKMS Educational meetings 2024-2025

- Spring and Autumn Education Days Approx £33,191
- UKMS Pharmacy Education Day 5 Nov 24 Wellcome Collection £2,392

### UKMRA

- 6th May 24 at the Wellcome Collection - £2,552 inc VAT
- Away Day 16-17 January 2025, Principle Hotel in York

### Breakdown of UKMRA Away Day January 2025 Conference Organiser: Hartley Taylor (HT)

Carried forward from 2024	£4,945
Income: Sponsorship raised for 2025	£36,000 ( J&J, Sanofi, Pfizer £11k each plus GSK £3k)
Total available for 2025	£40,945
Spend:	£22,902
HT fees:	£16,000
Spend breakdown	
Travel	£5,239
Venue & hotels	£14,375
AV	£2,398
HT travel & hotels	£890
C/F to 2026	£2,042

# THE UK MYELOMA SOCIETY

## TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

### Reserves

The UKMF's reserves remain sound as of 31 March 2025 and were approximately £572,469 (2024: £533,823). The investment is held to generate investment income for use within the Charity along with cash used to continue the Charity activities.

### Charitable bequests

- Kenneth Nightigale received on 15 October 2025 - £473
- David Owen received on 14 July 2025 - £12,500
- Lyn Nancy Corless received on 13 May 2025 - £5,000
- Martin John Francis Phipps received on 3 October 2025 - £5,000
- Rosemary Ludlam received October 2024 - £1,000
- Andrew Sharpe received November 2024 - £100
- Janice Margaret May: total to date £45,000
- Legacy of £15,000 received on 5 February 2025
- Interim payments followed:  
£25,000 received 12 March 2025  
£5,000 received on 3 July 2025.

### Trustees' responsibilities statement


The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

Signed by:  
  
.....A7B83086CBD1420.....  
**Dr J Ashcroft**  
Trustee

Date: 22-Jan-2026

---

# THE UK MYELOMA SOCIETY

---

**MENZIES**  
BRIGHTER THINKING

---

## INDEPENDENT EXAMINERS' REPORT

---

### Independent examiner's report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2025.

### Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:   
Janice Matthews FCA

Dated: 23-Jan-2026

**Menzies LLP**  
Chartered Accountants  
Magna House  
18-32 London Road  
Staines-Upon-Thames  
TW18 4BP



# THE UK MYELOMA SOCIETY

## STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Note	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
<b>Income from:</b>				
Donations and legacies	3	183,045	183,045	130,667
Investments	4	7,167	7,167	6,850
<b>Total income</b>		<b>190,212</b>	<b>190,212</b>	<b>137,517</b>
<b>Expenditure on:</b>				
Raising funds	5	1,545	1,545	1,488
Charitable activities	7	150,361	150,361	116,069
<b>Total expenditure</b>		<b>151,906</b>	<b>151,906</b>	<b>117,557</b>
<b>Net income before net gains on investments</b>		<b>38,306</b>	<b>38,306</b>	<b>19,960</b>
Net gains on investments	12	340	340	15,674
<b>Net movement in funds</b>		<b>38,646</b>	<b>38,646</b>	<b>35,634</b>
<b>Reconciliation of funds:</b>				
Total funds brought forward		533,823	533,823	498,189
Net movement in funds		38,646	38,646	35,634
<b>Total funds carried forward</b>		<b>572,469</b>	<b>572,469</b>	<b>533,823</b>

The Statement of financial activities includes all gains and losses recognised in the year.


The notes on pages 9 to 16 form part of these financial statements.

THE UK MYELOMA SOCIETY

BALANCE SHEET  
AS AT 31 MARCH 2025

	Note	2025 £	2024 £
<b>Fixed assets</b>			
Investments	12	251,532	199,044
		<u>251,532</u>	<u>199,044</u>
<b>Current assets</b>			
Cash at bank and in hand		334,637	347,353
		<u>334,637</u>	<u>347,353</u>
<b>Current liabilities</b>			
Creditors: amounts falling due within one year	13	(13,700)	(12,574)
		<u>(13,700)</u>	<u>(12,574)</u>
<b>Net current assets</b>		<u>320,937</u>	<u>334,779</u>
<b>Total assets less current liabilities</b>		<u>572,469</u>	<u>533,823</u>
<b>Total net assets</b>		<u><u>572,469</u></u>	<u><u>533,823</u></u>
<b>Charity funds</b>			
Designated funds	14	195,361	199,044
General funds	14	377,108	334,779
		<u>572,469</u>	<u>533,823</u>
<b>Total funds</b>		<u><u>572,469</u></u>	<u><u>533,823</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by:  
  
.....A7B83086CBD1420.....  
**Dr J Ashcroft**  
Trustee

Date: 22-Jan-2026

The notes on pages 9 to 16 form part of these financial statements.

---

# THE UK MYELOMA SOCIETY

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

---

### 1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

### 2. Accounting policies

#### 2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

#### 2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### 2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

---

# THE UK MYELOMA SOCIETY

---

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

---

### 2. Accounting policies (continued)

#### 2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

#### 2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

#### 2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

#### 2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

#### 2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

# THE UK MYELOMA SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Donations	183,045	183,045	130,667
Total 2024	130,667	130,667	

4. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from listed investments	5,693	5,693	5,366
Interest receivable	1,474	1,474	1,484
	7,167	7,167	6,850
Total 2024	6,850	6,850	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025

5. Investment management costs

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Investment management fees	1,545	1,545	1,488
<i>Total 2024</i>	<i>1,488</i>	<i>1,488</i>	

6. Analysis of grants

	Grants to Individuals 2025 £	Total funds 2025 £	Total funds 2024 £
Bursaries granted	8,151	8,151	6,000
<i>Total 2024</i>	<i>6,000</i>	<i>6,000</i>	

7. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Total 2025 £	Total 2024 £
Forum expenses	104,514	104,514	69,941
Website costs	5,726	5,726	3,422
Bank charges	260	260	2,094
Staff costs (see note 10)	34,833	34,833	37,132
Accountancy	5,028	5,028	3,480
	150,361	150,361	116,069
<i>Total 2024</i>	<i>116,069</i>	<i>116,069</i>	

# THE UK MYELOMA SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

### 8. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Grant funding of activities 2025 £	Support costs 2025 £	Total funds 2025 £	Total funds 2024 £
Forum expenses	96,363	8,151	-	104,514	69,941
Website costs	5,726	-	-	5,726	3,422
Service charges	260	-	-	260	2,094
Staff costs (see note 10)	-	-	34,833	34,833	37,132
Accountancy	-	-	5,028	5,028	3,480
	102,349	8,151	39,861	150,361	116,069
<i>Total 2024</i>	69,457	6,000	40,612	116,069	

### 9. Independent examiner's remuneration

	2025 £	2024 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	4,800	3,480

### 10. Staff costs

	2025 £	2024 £
Wages and salaries	34,004	36,357
Contribution to defined contribution pension schemes	829	775
	34,833	37,132

The average number of persons employed by the Charity during the year was as follows:

	2025 No.	2024 No.
Administration	1	1

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year ended 31 March 2025, expenses totalling £2,331 were reimbursed or paid directly to 8 Trustees (2024 - £1,604 to 10 Trustees).

12. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
<b>Cost or valuation</b>			
At 1 April 2024	198,744	300	199,044
Additions	79,846	(19,846)	60,000
Disposals	(29,014)	29,014	-
Revaluations	340	-	340
Funds withdrawn	-	(12,000)	(12,000)
Management fees	-	(1,545)	(1,545)
Dividend and interest income	-	5,693	5,693
At 31 March 2025	249,916	1,616	251,532
<b>Net book value</b>			
At 31 March 2025	249,916	1,616	251,532
At 31 March 2024	198,744	300	199,044

13. Creditors: Amounts falling due within one year

	2025 £	2024 £
Other taxation and social security	1,096	1,544
Pension fund loan payable	333	314
Other creditors	7,471	7,236
Accruals and deferred income	4,800	3,480
	13,700	12,574



# THE UK MYELOMA SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

### 14. Statement of funds

#### Statement of funds - current year

	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2025 £
<b>Designated funds</b>						
Michael Morley Investment Fund	199,044	5,693	(1,545)	(12,000)	4,169	195,361
<b>General funds</b>						
General Funds	334,779	184,519	(150,361)	12,000	(3,829)	377,108
<b>Total Unrestricted funds</b>	<b>533,823</b>	<b>190,212</b>	<b>(151,906)</b>	<b>-</b>	<b>340</b>	<b>572,469</b>

#### Statement of funds - prior year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2024 £
<b>Designated funds</b>						
Michael Morley Investment Fund	275,492	5,366	(1,488)	(96,000)	15,674	199,044
<b>General funds</b>						
General Funds	222,697	132,151	(116,069)	96,000	-	334,779
<b>Total Unrestricted funds</b>	<b>498,189</b>	<b>137,517</b>	<b>(117,557)</b>	<b>-</b>	<b>15,674</b>	<b>533,823</b>

The designated fund is used to hold the Charity's investments and generate income.

# THE UK MYELOMA SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2025 £	Total funds 2025 £
Fixed asset investments	251,532	251,532
Current assets	334,637	334,637
Creditors due within one year	(13,700)	(13,700)
<b>Total</b>	<b>572,469</b>	<b>572,469</b>

Analysis of net assets between funds - prior year

	Unrestricted funds 2024 £	Total funds 2024 £
Fixed asset investments	199,044	199,044
Current assets	347,353	347,353
Creditors due within one year	(12,574)	(12,574)
<b>Total</b>	<b>533,823</b>	<b>533,823</b>

16. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2025.